In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural fragment Cosyntropin | Natural peptide Oxytocin | |
|---|---|---|---|
| Identity | |||
| Kind | Natural fragment | Natural peptide | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 97 | 3,492 (plus 1,148 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 6 (6 in people) | 157 (152 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 27 · 4 active13 more mention it but do not test it | 690 · 65 active238 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Cortrosyn says: “Diagnostic screening of adrenocortical insufficiency in adults and pediatric patients, in combination with other diagnostic tests”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Cosyntropin | Oxytocin |
|---|---|---|
| Adverse eventsWhole body | 55 | 1261233 |
| Receptor activity and mechanismReproductive and sexual health |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Pitocin says: “Antepartum: medically indicated induction of labor, stimulation or reinforcement of labor, adjunctive therapy in incomplete or inevitable abortion” No central EU authorisation (EMA).
6222
28960801472 |
| PainNervous system and cognition | 2121 | 1098524 |
|---|
| PharmacokineticsPharmacology | 88 | 9168203 |
|---|
| Appetite and food intakeMetabolic and weight | 22 | 946727 |
|---|
| Stress hormonesEndocrine and hormones | 312 | 7560123 |
|---|
| Exercise and physical functionNervous system and cognition | 11 | 1717 |
|---|
| Gastrointestinal protectionGastrointestinal | 77 | 918 |
|---|
| Bone and jointMusculoskeletal | 33 | 2020 |
|---|
| NeuroprotectionNervous system and cognition | 99 | 844 |
|---|
| Respiratory functionRespiratory | 11 | 44 |
|---|
| MortalityWhole body | 22 | 22 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Cosyntropin is the same as Corticotropin residues 1 to 24.
No differences in the aligned region.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Cosyntropin | Oxytocin |
|---|---|---|
| Exercise and physical functionNervous system and cognitionCompared as: difference from placebo, in kg | No comparable result 1 randomized-trial result measure it in another way or another unit. | 2.25 kg Whole body lean mass difference Dose studied: 24 IU 4 times per day8 weeksn = 212021 |
| Stress hormonesEndocrine and hormonesCompared as: value in the arm that got the peptide, in ng/l | No comparable result 1 randomized-trial result measure it in another way or another unit. | 266 ng/l Peak plasma ACTH Saline: 281 ng/l n = 61988 |
| PainNervous system and cognitionCompared as: difference from placebo, in % | No comparable result 20 randomized-trial results measure it in another way or another unit. | −11% allodynic area change Dose studied: 100 µgn = 52023 |
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in effect size | No randomized trial result 8 results from other study designs. | −1.12 effect size Effect size Dose studied: 48 IU/day6 weeksn = 1032020 |
| Gastrointestinal protectionGastrointestinalCompared as: value in the arm that got the peptide, in % | 37% No nausea Dose studied: 3 mg on D1 and 2 mg/d on D2 and D33 daysn = 1021989 | No randomized trial result 9 results from other study designs. |
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in kcal | No randomized trial result 2 results from other study designs. | −152 kcal Difference in caloric intake Dose studied: 24 IU four times daily8 weeksn = 612024 |
| Intensive care and hospital outcomesWhole bodyCompared as: value in the arm that got the peptide, in day | 1 day Hospital stay difference Dose studied: 1 mgsingle dosen = 442025 | |
| Receptor activity and mechanismPharmacologyCompared as: value in the arm that got the peptide, in proteins | No randomized trial result 6 results from other study designs. | 198 proteins Differentially expressed proteins Dose studied: 24 IUsingle dosen = 192026 |
| Cell proliferation and differentiationNervous system and cognitionCompared as: value in the arm that got the peptide, in score | 78 score Mean VABS score · tetracosactide depot, SD 20.2 Dose studied: 0·5 mg on alternate daystwo weeksn not reported2023 | |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 5% Secondary effects Dose studied: 3 mg on D1 and 2 mg/d on D2 and D33 daysn = 1021989 | No comparable result 66 randomized-trial results measure it in another way or another unit. |
No comparable result
1 randomized-trial result measure it in another way or another unit.
2.25 kg
Whole body lean mass difference
Dose studied: 24 IU 4 times per day8 weeksn = 212021
No randomized trial result
1 result from other study designs.
No randomized trial result 1 result from other study designs. |
No comparable result
1 randomized-trial result measure it in another way or another unit.
266 ng/l
Peak plasma ACTH
Saline: 281 ng/l
n = 61988
No comparable result
20 randomized-trial results measure it in another way or another unit.
−11%
allodynic area change
Dose studied: 100 µgn = 52023
No randomized trial result
8 results from other study designs.
−1.12 effect size
Effect size
Dose studied: 48 IU/day6 weeksn = 1032020
37%
No nausea
Dose studied: 3 mg on D1 and 2 mg/d on D2 and D33 daysn = 1021989
No randomized trial result
9 results from other study designs.
No randomized trial result
2 results from other study designs.
−152 kcal
Difference in caloric intake
Dose studied: 24 IU four times daily8 weeksn = 612024
1 day
Hospital stay difference
Dose studied: 1 mgsingle dosen = 442025
No randomized trial result
1 result from other study designs.
No randomized trial result
6 results from other study designs.
198 proteins
Differentially expressed proteins
Dose studied: 24 IUsingle dosen = 192026
78 score
Mean VABS score · tetracosactide depot, SD 20.2
Dose studied: 0·5 mg on alternate daystwo weeksn not reported2023
No randomized trial result
1 result from other study designs.
5%
Secondary effects
Dose studied: 3 mg on D1 and 2 mg/d on D2 and D33 daysn = 1021989
No comparable result
66 randomized-trial results measure it in another way or another unit.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 27 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
University of Virginia100 participants29 Jan 2018 to 12 Mar 2019
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia · Lecithin Acyltransferase Deficiency
University of California, San Diego50 participantsFeb 2010 to Jul 2014
Development
United States Naval Medical Center, San Diego29 participantsAug 2010 to Apr 2014
Postdural Puncture Headache
13 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 690 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
University of Alabama at Birmingham1,798 participantsNov 2008 to Jun 2010
Uterine Atony · Postpartum Hemorrhage
Northwestern University1,003 participants28 Sept 2015 to 28 Sept 2020
Dystocia
University of Zimbabwe506 participants8 Apr 2018 to 30 Jun 2019
Post Partum Hemorrhage
238 more mention it but do not test it. They only measure it or name it in their text.